NCT05350384

Brief Summary

AN UNUSUAL ASSOCIATION BETWEEN PANCREATIC CANCER AND PURTSCHER-LIKE RETINOPATHY

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
1

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Jun 2021

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 18, 2021

Completed
1 month until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 31, 2021

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

November 1, 2021

Completed
5 months until next milestone

First Submitted

Initial submission to the registry

April 14, 2022

Completed
14 days until next milestone

First Posted

Study publicly available on registry

April 28, 2022

Completed
Last Updated

April 28, 2022

Status Verified

April 1, 2022

Enrollment Period

1 month

First QC Date

April 14, 2022

Last Update Submit

April 23, 2022

Conditions

Outcome Measures

Primary Outcomes (1)

  • funduscopic examination

    At the funduscopic examination the back of the eye showed large yellow spots and retinal hemorrhages in the superficial retina. In the early stages, fluorescein angiography showed hypofluorescence in the area of the yellow-white patches while the late stages showed hyperfluorescence

    at the onset of symptoms

Secondary Outcomes (1)

  • abdominal CT-scan

    at the onset of symptoms

Other Outcomes (2)

  • Unusual association between Purtscher-like retinopathy and a malignant disease (pancreatic cancer)

    at the diagnosis

  • Therapy

    after 1 month from diagnosis

Interventions

1 g. of methylprednisolone in saline solution 250 cc once a day for 5 days, and one eye drops of Diclofenac per eye 3 times a day for 30 days

Eligibility Criteria

Sexmale
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

No population, only one patient

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Eva Intagliata

Catania, 95123, Italy

Location

MeSH Terms

Conditions

Pancreatic Neoplasms

Interventions

Methylprednisolone

Condition Hierarchy (Ancestors)

Digestive System NeoplasmsNeoplasms by SiteNeoplasmsEndocrine Gland NeoplasmsDigestive System DiseasesPancreatic DiseasesEndocrine System Diseases

Intervention Hierarchy (Ancestors)

PrednisolonePregnadienetriolsPregnadienesPregnanesSteroidsFused-Ring CompoundsPolycyclic Compounds

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
researcher

Study Record Dates

First Submitted

April 14, 2022

First Posted

April 28, 2022

Study Start

June 18, 2021

Primary Completion

July 31, 2021

Study Completion

November 1, 2021

Last Updated

April 28, 2022

Record last verified: 2022-04

Data Sharing

IPD Sharing
Will not share

Locations